Biovica Int (BIOVIC), Sweden based novel breast cancer test company is reporting tomorrow.
BIOVIC is down 50% due to delay of FDA approval due to FDA covid congestion. The thesis is unchanged. FDA covid related delay should not change the valuation.
https://fitinvestmentideas.com/2021/11/30/biovica-our-doubling-candidate-is-reporting-tomorrow/
BIOVIC is down 50% due to delay of FDA approval due to FDA covid congestion. The thesis is unchanged. FDA covid related delay should not change the valuation.
https://fitinvestmentideas.com/2021/11/30/biovica-our-doubling-candidate-is-reporting-tomorrow/
30/11 2021 18:00 Makingmoney 1
99032 God tekst at læse når man har en pæn stak, ikke mindst linjen under overskriften. Nå, seriøst er det en af de mere sikre bioteks. Belønningen er nu ikke længere ude i kimningen, men lige ude over rælingen
